Defence Therapeutics Income Statement

Financials in millions CAD. Fiscal year is July - June.

Millions CAD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Selling, General & Admin	2.59	1.52	2.96	2.6	3.14
Research & Development	1.44	0.8	3.86	3.58	3.76
Amortization of Goodwill & Intangibles	-	-	0.04	0.01	-
Operating Expenses	4.93	3.19	12.75	6.49	7.27
Operating Income	-4.93	-3.19	-12.75	-6.49	-7.27
Interest Expense	-0.41	-0.32	-0.4	-0.26	-
Interest & Investment Income	0	0	0.02	0.01	-
Currency Exchange Gain (Loss)	-0.03	-0.01	0	-0.07	-0.02
Other Non Operating Income (Expenses)	-1.41	-0.08	-0.08	-0.05	-0.05
EBT Excluding Unusual Items	-6.78	-3.6	-13.19	-6.87	-7.34
Other Unusual Items	-	0.08	-	-	-
Pretax Income	-6.78	-3.52	-13.19	-6.87	-7.34
Income Tax Expense	-0.09	-	-	-0.11	-
Net Income	-6.7	-3.52	-13.19	-6.76	-7.34
Net Income to Common	-6.7	-3.52	-13.19	-6.76	-7.34
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	62	50	45	40	36
Shares Outstanding (Diluted)	62	50	45	40	36
Shares Change	24.78%	11.64%	12.54%	9.93%	35.65%
EPS (Basic)	-0.11	-0.07	-0.30	-0.17	-0.20
EPS (Diluted)	-0.11	-0.07	-0.30	-0.17	-0.20
EPS Growth	-	-	-	-	-

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Free Cash Flow	-4.76	-3.4	-4.49	-7.72	-6.04
Free Cash Flow Per Share	-0.08	-0.07	-0.10	-0.20	-0.17
EBITDA	-4.86	-3.14	-12.68	-6.48	-
D&A For EBITDA	0.07	0.05	0.07	0.01	-
EBIT	-4.93	-3.19	-12.75	-6.49	-7.27
Advertising Expenses	1.14	0.53	1.71	1.96	2.52